Carlos Almeida Ramos, MD, PhD, Baylor College of Medicine, Houston, TX, discusses the benefits of CD30-targeting CAR-modified Epstein-Barr virus-specific T-cells (CD30.CAR EBVSTs), a type of CAR-T cell modified to only react against EBV antigens, avoiding the risk of graft-versus-host disease (GvHD). Prof. Almeida Ramos describes how this ‘off-the-shelf’ CAR-T product may allow patients with Hodgkin lymphoma (HL) to be treated quickly and may benefit patients whose own immune cells are damaged. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
